secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-10-01T11:57:57+00:00
Accession:  0001213900-26-105453
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nektar's rezpegaldesleukin shows durable hair regrowth in alopecia areata; Phase 3 ZENITH AA to start early 2027
--------------------------------------------------------------------------------

- Alopecia areata: SALT Score ≤20 response maintained in 75% (6/8) at 4 months off treatment and 63% (5/8) at 6 months; SALT ≤10 deepened from 7% at Week 52 to 19% off treatment.
- REZOLVE-AA: Week 36-52, 29% low dose (18 µg/kg) and 31% high dose (24 µg/kg) achieved new SALT ≤20 vs none on placebo; 850-patient Phase 3 ZENITH AA starts early 2027.
- Atopic dermatitis REZOLVE-AD: maintenance Q4W raised EASI-100 from 4% to 22%; Q12W from 9% to 18%; among prior responders, Q4W 6% to 30%, Q12W 14% to 27%.
- Third Phase 3 ZENITH AD study initiated in treatment-experienced atopic dermatitis; safety through 52 weeks favorable and consistent with prior profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/0001213900-26-105453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/ea0307306-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-105453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer